Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease;exenatide melhora o diabetes tipo 2 de ocorrência concomitante com doença hepática gordurosa não alcoólica

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 57, Issue 9, 2013, Pages 702-708

  Fan, Hui ^a   Pan, Qingrong ^a   Xu, Yuan ^a   Yang, Xinchun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Exenatide; Metformin; Non alcoholic fatty liver disease; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; EXENDIN 4; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; METFORMIN; PEPTIDE; VENOM;

ADULT; AGED; ARTICLE; BLOOD; BODY MASS; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; WAIST HIP RATIO;

ADIPONECTIN; ADULT; AGED; ALANINE TRANSAMINASE; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; TIME FACTORS; TREATMENT OUTCOME; VENOMS; WAIST-HIP RATIO;

EID: 84892421783     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302013000900005     Document Type: Article

References (25)

1. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50 (1):171-180.
2. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090-1101.
3. Leavens K F, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol. 2011;46:200-215.
4. Targher G, Day C P, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341-1350.
5. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005;100(5):1072-1081.
6. Wang R T, Koretz RL, Yee HF Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med. 2003;115(7):554-559.
7. Kadayifci A, Merriman RB, Bass NM. Medical treatment of nonalcoholic steatohepatitis. Clin Liver Dis. 2007;11(1):119-140.
8. Musso G, Gambino R, Cassader M. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52(1):79-104.
9. Eng J, Kleinman WA, Singh L, Singh G, Raufman J P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 1992;267(11):7402-7405.
10. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43(1):173-181.
11. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275-286.
12. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab. 2004;89(6):2583-2589.
13. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76-79.
14. Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, et al. C-reactive protein levels in relation to various features of nonalcoholic fatty liver disease among obese patients. J Hepatol. 2011;55(3):660-665.
15. Arvaniti VA, Thomopoulos KC, Tsamandas A, Makri M, Psyrogiannis A, Vafadis G, et al. Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinfammation and fbrosis. Acta Gastroenterol Belg. 2008;71(4):355-360.
16. Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22(6):437-443.
17. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54(11):3140-3147.
18. Pacana T, Fuchs M. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. Clin Liver Dis. 2012;16(3):599-613.
19. Ali R, Cusi K. New diagnostic and treatment approaches in nonalcoholic fatty liver disease (NAFLD). Ann Med. 2009;41(4):265-278.
20. American Gastroenterological Association. American Gastroente-rological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1702-4.
21. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al.; American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientifc statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162-172.
22. Gallwitz B. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. Drugs. 2011;71(13):1675-1688.
23. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33(8):1734-1737.
24. Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011;4(4):249-263.
25. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31(9):1285-1297.